Moreover, the contribution of the mutant JAK2 in myeloproliferative diseases, polycythemia vera, adult T-cell lymphoblastic leukemias, acute lymphoblastic leukemia, and Hodgkin lymphoma (HL) has been reported (Marubayashi et al., 2010; Harry et al., 2012; Kalkat et al., 2017; Johnson et al., 2018). Here, JAK2 is linked to myeloproliferative disorder.